Poviderm SOL

Hauptinformation

  • Handelsname:
  • Poviderm SOL Lösung zur Anwendung auf der Haut
  • Darreichungsform:
  • Lösung zur Anwendung auf der Haut
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Poviderm SOL Lösung zur Anwendung auf der Haut
    Belgien
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • AFMPS - Agence Fédérale des Médicaments et des Produits de Santé - Belgium
  • Zulassungsnummer:
  • BE-V196971
  • Letzte Änderung:
  • 17-04-2018

Packungsbeilage

Bijsluiter – DE versie

Poviderm Sol

GEBRAUCHSINFORMATION

POVIDERM SOL

Gebrauchsfertige alkoholische Lösung von Povidon-Jod.

1.

NAME

UND

ANSCHRIFT

DES

ZULASSUNGSINHABERS

UND,

WENN

UNTERSCHIEDLICH, DES HERSTELLERS, DER FÜR DIE CHARGENFREIGABE

VERANTWORTLICH IST

Zulassungsinhaber:

Emdoka bvba, John Lijsenstraat 16, B-2321 Hoogstraten, Belgien.

Für die Chargenfreigabe verantwortlicher Hersteller:

Laboratorium Smeets nv, B-2610 Wilrijk.

2.

BEZEICHNUNG DES TIERARZNEIMITTELS

POVIDERM SOL Povidonum iodinatum

Desinfektionslösung

3.

WIRKSTOFF(E) UND SONSTIGE BESTANDTEILE

1 Gramm Lösung enthält:

30 mg Povidonum Iodinatum, eq. 3 mg Jod, Glycerol, Macrogol 300, Nonoxynol-9, Dinatrii phosphas

dodecahydricus, Zitronensäure monohydrat, Isopropanol, gereinigtes Wasser.

4.

ANWENDUNGSGEBIET(E)

Unterstützende Behandlung bei der Prävention von Haut- und Wundinfektionen.

5.

GEGENANZEIGEN

Povidon-Jod darf nicht langzeitig oder wiederholt auf hoch differenzierte Gewebe, wie Muskeln,

Sehnen, Nerven und Knorpel angewendet werden.

Dieses Präparat darf nicht bei Allergie gegen Jod oder einen anderen Bestandteil angewendet werden.

6.

NEBENWIRKUNGEN

Nach längerer Behandlung kann eine Verzögerung in der Genesung von Haut und Wunden eintreten.

Trotzdem, dass Povidon-Jod auf der Haut gut vertragen wird, kann eine lokale Irritation auftreten,

besonders nach häufigem Verabreichen.

Der Gebrauch auf großen Hautoberflächen während langer Zeit kann bestimmte schwere allgemeine

Nebenwirkungen hervorrufen.

7.

ZIELTIERART(EN)

Hund, Kaninchen.

8.

DOSIERUNG FÜR JEDE TIERART, ART UND DAUER DER ANWENDUNG

Die unverdünnte Lösung gleichmäßig auf die betroffenen Hautoberflächen und Wunden anbringen, bis

diese vollständig mit einem dünnen homogenen Film bedeckt sind.

Diese Behandlung soll eventuell mehrmals am Tag wiederholt werden, bis man eine deutlich sichtbare

Besserung der betroffenen Hautoberflächen feststellt.

9.

HINWEISE FÜR DIE RICHTIGE ANWENDUNG

Keine.

10.

WARTEZEIT

Nicht zutreffend.

Bijsluiter – DE versie

Poviderm Sol

11.

BESONDERE LAGERUNGSHINWEISE

Nicht direktem Sonnenlicht aussetzen.

Die Haltbarkeit des Präparates in der Originalverpackung: 3 Jahre.

Die Haltbarkeit nach erstmaligem Öffnen des Behälters: 28 Tage.

Arzneimittel unzugänglich für Kinder aufbewahren.

12.

BESONDERE WARNHINWEISE

Besondere Vorsichtsmaßnahmen für die Anwendung bei Tieren:

Kontakt mit den Augen vermeiden.

Bei Behandlung von großen Hautoberflächen, oder bei langzeitiger Verabreichung muss eine

mögliche Jodresorption durch die Haut berücksichtigt werden.

Besondere Vorsichtsmaßnahmen für den Anwender:

Personen mit bekannter Überempfindlichkeit gegenüber Povidon-Jod, Povidon oder Jod sollten jeden

Kontakt mit diesem Tierarzneimittel vermeiden. Bei der Handhabung des Tierarzneimittels muss der

Anwender Handschuhe und Schutzkleidung tragen. Im Falle einer Aussetzung von Augen oder Haut,

unmittelbar mit Wasser abspülen oder waschen. Konsultieren Sie einen Arzt wenn allergische

Hautreaktionen eintreten. Schwellungen vom Gesicht, der Lippen oder Augen sind schwerere

Symptome von Allergie bei denen unverzügliche ärztliche Hilfe notwendig ist.

Im Falle einer zufälligen Einnahme müssen Sie sofort einen Arzt konsultieren und ihm die

Packungsbeilage oder das Etikett zeigen.

Nicht gleichzeitig mit anderen Antiseptika oder anderen lokalen Arzneimitteln anwenden. Nicht mit

Wasserstoffperoxid, Quecksilberderivaten und Natriumsulfat anwenden.

Anwendung während der Trächtigkeit und Laktation:

Povidon-Jod kann während der Trächtigkeit oder Laktation angewendet werden.

Überdosierung (Symptome, Notfallmaßnahmen, Gegenmittel):

In Anbetracht der relativ niedrigen Toxizität dieses Antiseptikums, ist die Wahrscheinlichkeit klein,

dass bei übermäßigem Gebrauch toxische Auswirkungen eintreten könnten.

13.

BESONDERE VORSICHTSMASSNAHMEN FÜR DIE ENTSORGUNG VON NICHT

VERWENDETEM ARZNEIMITTEL ODER VON ABFALLMATERIALIEN, SOFERN

ERFORDERLICH

Nicht verwendete Tierarzneimittel oder davon stammende Abfallmaterialien sind entsprechend den

lokalen Vorschriften zu entsorgen.

Poviderm Sol darf nicht in das Abwasser gelangen, weil dies Gefahr für die im Wasser lebenden

Organismen verursachen kann.

14.

GENEHMIGUNGSDATUM DER PACKUNGSBEILAGE

07/2010

15.

WEITERE ANGABEN

Verpackung: Plastikflaschen mit 230 g, 460 g, 920 g, 1840 g, 2300 g oder 4600 g antiseptischer

Lösung.

Es werden möglicherweise nicht alle Packungsgrössen in Verkehr gebracht.

Frei erhältlich.

BE-V196971

Verteiler:

Ecuphar NV, Legeweg 157I, B-8020 Oostkamp

Tel: 050/ 31 42 69

17-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Published on: Fri, 16 Nov 2018 The food enzyme is an endo‐1,4‐β‐xylanase (EC 3.2.1.8) produced with a genetically modified strain of Aspergillus oryzae by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This xylanase is intended to be used in baking and cereal‐based processes. Based on the proposed maximum use levels, dietary exposure to the food enzyme–total organic solids (TOS) was e...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐α‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐SO by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme–total organi...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucan 1,4‐α‐glucosidase (EC 3.2.1.3) is produced with the genetically modified Aspergillus niger strain NZYM‐BW by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucan 1,4‐α‐glucosidase food enzyme is intended to be used in distilled alcohol production and starch processing for the production of glucose syrups. Residu...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucoamylase (glucan 1,4‐α‐glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Residual amounts of total organic s...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Published on: Tue, 23 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for sows in order to have benefit in piglets. The additive HOSTAZYM® X contains endo‐1,4‐beta‐xylanase and is available in liquid and solid formulations. This product is authorised as a feed additive for chickens for fattening, tu...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 10 Aug 2018 00:00:00 +0200 This scientific opinion of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) deals with the safety evaluation of the recycling process General Plastic (EU register No RECYC153), which is based on the Starlinger Decon technology. The decontamination efficiency of the process was demonstrated by a challenge test. The input of this process is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes orig...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

Soliris 300 mg Konzentrat

Rote - Liste

26-9-2018

Today, Wednesday, September 26th 2018 at 12 pm EST is the last day that the #FDA will be soliciting site visit proposals for the 2018 Experiential Learning Program. Click the link to find more about the program & submit your application:   http://go.usa.g

Today, Wednesday, September 26th 2018 at 12 pm EST is the last day that the #FDA will be soliciting site visit proposals for the 2018 Experiential Learning Program. Click the link to find more about the program & submit your application: http://go.usa.g

Today, Wednesday, September 26th 2018 at 12 pm EST is the last day that the #FDA will be soliciting site visit proposals for the 2018 Experiential Learning Program. Click the link to find more about the program & submit your application: http://go.usa.gov/xPrum  #MedicalDevice pic.twitter.com/Zsmq00NCdd

FDA - U.S. Food and Drug Administration

19-9-2018

Reminder: #FDA site visit proposal solicitation period for the 2018  Experiential Learning Program is currently OPEN through Wednesday,  9/26/18 @ 12 pm EST. Click the link to find more about the  program & to submit your application  https://go.usa.gov/x

Reminder: #FDA site visit proposal solicitation period for the 2018 Experiential Learning Program is currently OPEN through Wednesday, 9/26/18 @ 12 pm EST. Click the link to find more about the program & to submit your application https://go.usa.gov/x

Reminder: #FDA site visit proposal solicitation period for the 2018 Experiential Learning Program is currently OPEN through Wednesday, 9/26/18 @ 12 pm EST. Click the link to find more about the program & to submit your application https://go.usa.gov/xPrum  #MedicalDevice pic.twitter.com/FN1mNN65dD

FDA - U.S. Food and Drug Administration

12-9-2018

The FDA site visit proposal solicitation period for the 2018 Experiential Learning Program is currently OPEN through Wednesday, September 26th 2018 12 pm EST. Click the link to find more about the program & to submit your application  https://go.usa.gov/x

The FDA site visit proposal solicitation period for the 2018 Experiential Learning Program is currently OPEN through Wednesday, September 26th 2018 12 pm EST. Click the link to find more about the program & to submit your application https://go.usa.gov/x

The FDA site visit proposal solicitation period for the 2018 Experiential Learning Program is currently OPEN through Wednesday, September 26th 2018 12 pm EST. Click the link to find more about the program & to submit your application https://go.usa.gov/xPrum  #FDA #MedicalDevice pic.twitter.com/Kyo5z44Os4

FDA - U.S. Food and Drug Administration

5-9-2018

The FDA's site visit proposal solicitation period for the 2018 Experiential Learning Program is currently OPEN through Wednesday, September 26th 2018 at 12 pm EST. Click the link to find more about the program and to submit your application:  https://go.u

The FDA's site visit proposal solicitation period for the 2018 Experiential Learning Program is currently OPEN through Wednesday, September 26th 2018 at 12 pm EST. Click the link to find more about the program and to submit your application: https://go.u

The FDA's site visit proposal solicitation period for the 2018 Experiential Learning Program is currently OPEN through Wednesday, September 26th 2018 at 12 pm EST. Click the link to find more about the program and to submit your application: https://go.usa.gov/xPcpn  #MedicalDevice

FDA - U.S. Food and Drug Administration

23-3-2018

EU/3/18/2001 (Soligenix UK Ltd)

EU/3/18/2001 (Soligenix UK Ltd)

EU/3/18/2001 (Active substance: Recombinant modified ricin toxin A-chain subunit) - Orphan designation - Commission Decision (2018)1889 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/242/17

Europe -DG Health and Food Safety